1
|
Gao W, Xu Y, Liu H, Gao M, Cao Q, Wang Y, Cui L, Huang R, Shen Y, Li S, Yang H, Chen Y, Li C, Yu H, Li W, Shen G. Characterization of missense mutations in the signal peptide and propeptide of FIX in hemophilia B by a cell-based assay. Blood Adv 2020; 4:3659-3667. [PMID: 32766856 PMCID: PMC7422117 DOI: 10.1182/bloodadvances.2020002520] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2020] [Accepted: 07/06/2020] [Indexed: 11/20/2022] Open
Abstract
Many mutations in the signal peptide and propeptide of factor IX (FIX) cause hemophilia B. A FIX variants database reports 28 unique missense mutations in these regions that lead to FIX deficiency, but the underlying mechanism is known only for the mutations on R43 that interfere with propeptide cleavage. It remains unclear how other mutations result in FIX deficiency and why patients carrying the same mutation have different bleeding tendencies. Here, we modify a cell-based reporter assay to characterize the missense mutations in the signal peptide and propeptide of FIX. The results show that the level of secreted conformation-specific reporter (SCSR), which has a functional γ-carboxyglutamate (Gla) domain of FIX, decreases significantly in most mutations. The decreased SCSR level is consistent with FIX deficiency in hemophilia B patients. Moreover, we find that the decrease in the SCSR level is caused by several distinct mechanisms, including interfering with cotranslational translocation into the endoplasmic reticulum, protein secretion, γ-carboxylation of the Gla domain, and cleavage of the signal peptide or propeptide. Importantly, our results also show that the SCSR levels of most signal peptide and propeptide mutations increase with vitamin K concentration, suggesting that the heterogeneity of bleeding tendencies may be related to vitamin K levels in the body. Thus, oral administration of vitamin K may alleviate the severity of bleeding tendencies in patients with missense mutations in the FIX signal peptide and propeptide regions.
Collapse
Affiliation(s)
- Wenwen Gao
- Department of Medical Genetics, Institute of Hemostasis and Thrombosis, School of Basic Medical Sciences, and
| | - Yaqi Xu
- Department of Medical Genetics, Institute of Hemostasis and Thrombosis, School of Basic Medical Sciences, and
| | - Hongli Liu
- Department of Medical Genetics, Institute of Hemostasis and Thrombosis, School of Basic Medical Sciences, and
| | - Meng Gao
- Department of Medical Genetics, Institute of Hemostasis and Thrombosis, School of Basic Medical Sciences, and
| | - Qing Cao
- Department of Medical Genetics, Institute of Hemostasis and Thrombosis, School of Basic Medical Sciences, and
| | - Yiyi Wang
- Department of Medical Genetics, Institute of Hemostasis and Thrombosis, School of Basic Medical Sciences, and
| | - Longteng Cui
- Department of Medical Genetics, Institute of Hemostasis and Thrombosis, School of Basic Medical Sciences, and
| | - Rong Huang
- Department of Medical Genetics, Institute of Hemostasis and Thrombosis, School of Basic Medical Sciences, and
| | - Yan Shen
- Department of Medical Genetics, Institute of Hemostasis and Thrombosis, School of Basic Medical Sciences, and
| | - Sanqiang Li
- Department of Medical Genetics, Institute of Hemostasis and Thrombosis, School of Basic Medical Sciences, and
| | - Haiping Yang
- Department of Medical Genetics, Institute of Hemostasis and Thrombosis, School of Basic Medical Sciences, and
- First Affiliated Hospital, Henan University of Science and Technology, Luoyang, People's Republic of China
| | - Yixiang Chen
- Department of Medical Genetics, Institute of Hemostasis and Thrombosis, School of Basic Medical Sciences, and
| | - Chaokun Li
- Sino-UK Joint Laboratory for Brain Function and Injury, School of Basic Medical Sciences, and
| | - Haichuan Yu
- Department of Biochemistry and Molecular Biology, School of Medical Laboratory, Xinxiang Medical University, Xinxiang, People's Republic of China; and
| | - Weikai Li
- Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO
| | - Guomin Shen
- Department of Medical Genetics, Institute of Hemostasis and Thrombosis, School of Basic Medical Sciences, and
| |
Collapse
|
2
|
Hao Z, Jin DY, Stafford DW, Tie JK. Vitamin K-dependent carboxylation of coagulation factors: insights from a cell-based functional study. Haematologica 2019; 105:2164-2173. [PMID: 31624106 PMCID: PMC7395276 DOI: 10.3324/haematol.2019.229047] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2019] [Accepted: 10/11/2019] [Indexed: 12/21/2022] Open
Abstract
Vitamin K-dependent carboxylation is a post-translational modification essential for the biological function of coagulation factors. Defects in carboxylation are mainly associated with bleeding disorders. With the discovery of new vitamin K-dependent proteins, the importance of carboxylation now encompasses vascular calcification, bone metabolism, and other important physiological processes. Our current knowledge of carboxylation, however, comes mainly from in vitro studies carried out under artificial conditions, which have a limited usefulness in understanding the carboxylation of vitamin K-dependent proteins in native conditions. Using a recently established mammalian cell-based assay, we studied the carboxylation of coagulation factors in a cellular environment. Our results show that the coagulation factor’s propeptide controls substrate binding and product releasing during carboxylation, and the propeptide of factor IX appears to have the optimal affinity for efficient carboxylation. Additionally, non-conserved residues in the propeptide play an important role in carboxylation. A cell-based functional study of naturally occurring mutations in the propeptide successfully interpreted the clinical phenotype of warfarin’s hypersensitivity during anticoagulation therapy in patients with these mutations. Unlike results obtained from in vitro studies, results from our cell-based study indicate that although the propeptide of osteocalcin cannot direct the carboxylation of the coagulation factor, it is required for the efficient carboxylation of osteocalcin. This suggests that the coagulation factors may have a different mechanism of carboxylation from osteocalcin. Together, results from this study provide insight into efficiently controlling one physiological process, such as coagulation without affecting the other, like bone metabolism.
Collapse
Affiliation(s)
- Zhenyu Hao
- Department of Biology, the University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Da-Yun Jin
- Department of Biology, the University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Darrel W Stafford
- Department of Biology, the University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Jian-Ke Tie
- Department of Biology, the University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| |
Collapse
|
3
|
Lindsay M, Gil GC, Cadiz A, Velander WH, Zhang C, Van Cott KE. Purification of recombinant DNA-derived factor IX produced in transgenic pig milk and fractionation of active and inactive subpopulations. J Chromatogr A 2004; 1026:149-57. [PMID: 14763741 DOI: 10.1016/j.chroma.2003.11.006] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Transgenic animal bioreactors can be engineered to make gram per liter quantities of complex recombinant glycoproteins in milk. However, little is known about the limitations in post-translational processing that occurs for very complex proteins and how this impacts the task of purification. We report on the purification of recombinant factor IX (rFIX) from the milk of transgenic pigs having an expression level of 2-3 g rFIX/(l(-1) h(-1)), an expression level that is about 20-fold higher than previously reported. This purification process efficiently recovers highly active rFIX and shows that even complex mixtures like pig milk, which contains 60 g/l total endogenous milk protein and multiple subpopulations of rFIX, can be processed using conventional, non-immunoaffinity chromatographic methods. Without prior removal of caseins, heparin-affinity chromatography was used to first purify the total population of rFIX at greater than 90% yield. After the total population was isolated, the biologically active and inactive subpopulations were fractionated by high-resolution anion exchange chromatography using an ammonium acetate elution. Capillary isoelectric focusing of the active and inactive rFIX fractions demonstrated that the active subpopulations are the most acidic.
Collapse
Affiliation(s)
- Myles Lindsay
- Department of Chemical Engineering, 133 Randolph Hall, Virginia Tech, Blacksburg, VA 24061, USA
| | | | | | | | | | | |
Collapse
|
4
|
Aktimur A, Gabriel MA, Gailani D, Toomey JR. The factor IX gamma-carboxyglutamic acid (Gla) domain is involved in interactions between factor IX and factor XIa. J Biol Chem 2003; 278:7981-7. [PMID: 12496253 DOI: 10.1074/jbc.m212748200] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
During hemostasis, factor IX is activated to factor IXabeta by factor VIIa and factor XIa. The glutamic acid-rich gamma-carboxyglutamic acid (Gla) domain of factor IX is involved in phospholipid binding and is required for activation by factor VIIa. In contrast, activation by factor XIa is not phospholipid-dependent, raising questions about the importance of the Gla for this reaction. We examined binding of factors IX and IXabeta to factor XIa by surface plasmon resonance. Plasma factors IX and IXabeta bind to factor XIa with K(d) values of 120 +/- 11 nm and 110 +/- 8 nm, respectively. Recombinant factor IX bound to factor XIa with a K(d) of 107 nm, whereas factor IX with a factor VII Gla domain (rFIX/VII-Gla) and factor IX expressed in the presence of warfarin (rFIX-desgamma) did not bind. An anti-factor IX Gla monoclonal antibody was a potent inhibitor of factor IX binding to factor XIa (K(i) 34 nm) and activation by factor XIa (K(i) 33 nm). In activated partial thromboplastin time clotting assays, the specific activities of plasma and recombinant factor IX were comparable (200 and 150 units/mg), whereas rFIX/VII-Gla activity was low (<2 units/mg). In contrast, recombinant factor IXabeta and activated rFIX/VIIa-Gla had similar activities (80 and 60% of plasma factor IXabeta), indicating that both proteases activate factor X and that the poor activity of zymogen rFIX/VII-Gla was caused by a specific defect in activation by factor XIa. The data demonstrate that factor XIa binds with comparable affinity to factors IX and IXabeta and that the interactions are dependent on the factor IX Gla domain.
Collapse
Affiliation(s)
- Aysar Aktimur
- Department of Pathology, Vanderbilt University, Nashville, Tennessee 37232, USA
| | | | | | | |
Collapse
|
5
|
Isawa H, Yuda M, Yoneda K, Chinzei Y. The insect salivary protein, prolixin-S, inhibits factor IXa generation and Xase complex formation in the blood coagulation pathway. J Biol Chem 2000; 275:6636-41. [PMID: 10692472 DOI: 10.1074/jbc.275.9.6636] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Prolixin-S is a salivary anticoagulant of the blood-sucking insect, Rhodnius prolixus, and known as an inhibitor of the intrinsic Xase. We report here its inhibitory mechanisms with additional important anticoagulation activities. We found prolixin-S specifically bound to factor IX/IXa in the presence of Ca(2+) ions. Light scattering and surface plasmon resonance studies showed that prolixin-S interfered with factor IX/IXa binding to the phospholipid membrane, indicating that prolixin-S inhibit Xase activity of factor IXa by interference with its Xase complex formation. Furthermore, reconstitution experiments showed that prolixin-S binding to factor IX strongly inhibited factor IXa generation by factor XIa. We also found that prolixin-S inhibited factor IXa generation by factor VIIa-tissue factor complex and factor IXalpha generation by factor Xa. These results suggest that prolixin-S inhibits both intrinsic and extrinsic coagulations by sequential inhibition of all coagulation pathways in which factor IX participates. It was also suggested that prolixin-S may bind to factor IX/IXa by recognizing conformational change of the Gla domain induced by Ca(2+) binding.
Collapse
Affiliation(s)
- H Isawa
- Department of Medical Zoology, School of Medicine, Mie University, 2-174 Edobashi, Tsu 514-0001, Japan
| | | | | | | |
Collapse
|
6
|
Zwaal RF, Comfurius P, Bevers EM. Lipid-protein interactions in blood coagulation. BIOCHIMICA ET BIOPHYSICA ACTA 1998; 1376:433-53. [PMID: 9805008 DOI: 10.1016/s0304-4157(98)00018-5] [Citation(s) in RCA: 203] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
It has long been appreciated that lipids, particularly anionic phospholipids, promote blood coagulation. The last two decades have seen an increasing insight into the kinetic and mechanistic aspects regarding the mode of action of phospholipids in blood coagulation. This essay attempts to review these developments with particular emphasis on the structure of lipid-binding domains of blood coagulation proteins, and the variable effect of phospholipid composition on the interaction with these proteins. Some examples are discussed of how lipid membranes direct the pathway of enzymatic conversions in blood coagulation complexes, also illustrating that the membrane lipid surface is more than an inert platform for the assembly of coagulation factors. Finally, the controlled exposure of procoagulant lipid on the surface of blood cells is shortly reviewed, and an example is discussed of how interference with lipid-protein interactions in blood coagulation may result in pathological phenomena.
Collapse
Affiliation(s)
- R F Zwaal
- Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, P.O. Box 616, 6200 MD Maastricht, Netherlands
| | | | | |
Collapse
|